

ASX RELEASE

20 July 2020

**Annual General Meeting to be held Friday 18 September 2020**

Amplia Therapeutics Limited (ASX: ATX) ('Amplia' or the 'Company') advises that, in light of ongoing difficulties associated with the convening of public meetings due to the impact of COVID-19, its Annual General Meeting in respect of its financial year ended 31 March 2020 is to be held on Friday 18 September 2020.

The deferral of the AGM to this date is in accordance with ASIC's Media Release 20-113 "ASIC to further extend financial reporting deadlines for listed and unlisted entities and amends 'no action' position for AGMs" which confirmed that "ASIC has adopted a 'no action' position where public companies do not hold their Annual General Meetings (AGMs) within five months after the end financial years that end from 31 December 2019 to 7 July 2020, but do so up to seven months after year end".

Details of the meeting venue and other meeting arrangements will be confirmed at a later date.

In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by the Company not later than Thursday 30 July 2020.

This ASX announcement was approved and authorised for release by the Company Secretary.

- End -

**For Further Information**

Andrew J. Cooke  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).